Advertisement
Sinobiopharma,Inc. has announced that the company received a certificate for the use of Gabexatemesylate as a pharmaceutical raw material from theChinese State Food and Drug Administration ("SFDA").Gabexate Mesylate is a serine proteinase inhibitor used therapeutically inthe treatment of pancreatitis, disseminated intravascular coagulation (DIC),and as a regional anticoagulant for hemodialysis. The drug inhibits thehydrolytic effects of thrombin, plasmin, and kallikrein, but not ofchymotrypsin and aprotinin. The company is now awaiting GMP certification to manufacture Gabexatemesylate.
Advertisement
Advertisement